Anterior thalamic nuclei deep brain stimulation inhibits mossy fiber sprouting via 30,50-cyclic adenosine monophosphate/protein kinase A signaling pathway in a chronic epileptic monkey model

0
0
0

Anterior thalamic nuclei deep brain stimulation inhibits mossy fiber sprouting via 30,50-cyclic adenosine monophosphate/protein kinase A signaling pathway in a chronic epileptic monkey model

Epilepsy affects 0.5% to 1% of people worldwide, and for 30% of patients, standard medications fail to control seizures. For those with drug-resistant epilepsy—especially those with hard-to-locate seizure foci or foci in critical brain regions—deep brain stimulation (DBS) offers a lifeline. One of the most promising DBS targets is the anterior thalamic nuclei (ATN), a brain region that regulates seizure spread through the Papez circuit (a network linked to memory and emotion). Clinical studies show ATN-DBS reduces seizures by 41% in the first year and 69% after five years for drug-resistant patients—even better for those with temporal lobe epilepsy (TLE), the most common form. But until now, scientists didn’t know how ATN-DBS works in the chronic stage of epilepsy—when seizures have persisted for years and the brain has developed long-term, seizure-driving changes.

A 2021 study in Chinese Medical Journal by researchers from the Beijing Neurosurgical Institute and Beijing Tiantan Hospital addresses this gap. Using a monkey model of chronic epilepsy (closer to human biology than rodent models), the team found that ATN-DBS blocks a key pathological feature of TLE—mossy fiber sprouting (MFS)—by targeting the cAMP/PKA signaling pathway and reducing abnormal brain cell growth. Here’s what you need to know:

What’s the Problem with Chronic Epilepsy?

TLE is marked by mossy fiber sprouting—abnormal growth of unmyelinated axons (mossy fibers) from dentate granule cells. Normally, these fibers carry signals from the dentate gyrus (a hippocampal region) to the CA3 area (critical for memory). In epilepsy, they sprout backwards into the molecular layer of the dentate gyrus, creating a loop of overexcitation that lowers the threshold for seizures. Another driver: ectopic granule cells—brain cells that grow in the wrong place (the dentate hilus)—which add even more abnormal connections.

Most DBS research focuses on early-stage epilepsy, but 80% of patients seeking DBS have had seizures for 10+ years (the chronic stage). The team wanted to know if ATN-DBS could reverse MFS and its drivers in this phase.

How the Study Worked

The team tested 24 male rhesus monkeys (age 7–8 years, weight 8–10 kg), split into four groups:

  1. Control: No epilepsy (given saline instead of seizure-inducing chemicals).
  2. Epilepsy: Epilepsy induced with kainic acid (KA), a chemical that mimics glutamate (an excitatory neurotransmitter) and triggers status epilepticus (prolonged seizures).
  3. Epilepsy + Sham DBS: KA-induced epilepsy with DBS leads implanted but no electrical stimulation.
  4. Epilepsy + ATN-DBS: KA-induced epilepsy with 8 weeks of DBS (1.5V, 90ms, 150Hz) targeting the left ATN.

The study followed strict ethical guidelines (approved by the Beijing Neurosurgical Institute) and minimized animal suffering. After 3 months (when epilepsy became chronic), the team:

  • Measured cAMP (a molecule that activates PKA, a protein linked to cell growth and MFS) levels in hippocampal tissue.
  • Counted ectopic granule cells (using NeuN, a neuron marker) in the dentate hilus.
  • Scored MFS (using Calbindin-D28k, a mossy fiber marker) in the dentate gyrus and CA3 regions.

Key Findings: ATN-DBS Stops Chronic Seizures by Targeting MFS

The results were clear—and clinically meaningful:

  1. Fewer Seizures: The ATN-DBS group had 40% fewer seizures than the sham and epilepsy groups (statistically significant, p < 0.001).
  2. Fewer Ectopic Cells: Chronic epilepsy doubled the number of ectopic granule cells in the dentate hilus. ATN-DBS cut this number by 60% (p < 0.0001), reducing abnormal connections.
  3. Lower cAMP/PKA Levels: The epilepsy group had 50% higher cAMP and PKA levels (which promote MFS) than controls. ATN-DBS reversed this, with levels dropping to near-normal (p = 0.003 for cAMP, p = 0.0001 for PKA).
  4. Less MFS: MFS scores in the dentate gyrus and CA3 regions were 50% lower in the DBS group than in the sham and epilepsy groups (p < 0.0001).

These changes weren’t random—they were statistically significant, meaning they resulted from ATN-DBS, not chance.

What This Means for Epilepsy Treatment

This study fills a critical gap: it’s one of the first to show ATN-DBS works in chronic epilepsy—the stage most patients are in when they seek treatment. The findings suggest two key mechanisms:

  • Reducing Ectopic Granule Cells: These cells drive abnormal MFS by adding extra connections. ATN-DBS cuts their numbers, limiting overexcitation.
  • Blocking the cAMP/PKA Pathway: This pathway is like a “switch” for MFS—high cAMP/PKA levels turn it on. ATN-DBS turns it off, stopping mossy fibers from sprouting.

For patients, this is a game-changer. ATN-DBS isn’t just a “symptom reducer”—it targets the root cause of chronic seizures: abnormal brain wiring. The monkey model is especially powerful because their brains share 93% of human DNA, making the results more relevant to clinical practice.

Why This Matters for Research and Patients

The team’s work builds on their 2018 study in rats, where they found ATN-DBS inhibits MFS in acute and latent epilepsy. Now, they’ve shown it works in chronic epilepsy—aligning with real-world patient data (where ATN-DBS becomes more effective over time).

For researchers, this study highlights the cAMP/PKA pathway as a new target for anti-epileptic drugs. For patients, it confirms that ATN-DBS is a viable long-term option—even for those with decades of seizures.

The Bottom Line

Chronic epilepsy is defined by permanent brain changes, but this study shows those changes aren’t irreversible. ATN-DBS works by rewiring the brain: it cuts down on abnormal cells, blocks seizure-driving signaling, and stops mossy fibers from sprouting. For the 15 million people with drug-resistant epilepsy, this is hope—proof that DBS isn’t just a last resort, but a therapy that targets the biology of chronic seizures.

The study was led by Ting-Ting Du and Ying-Chuan Chen (co-first authors) and Jian-Guo Zhang (corresponding author) from the Department of Functional Neurosurgery at the Beijing Neurosurgical Institute and Department of Neurosurgery at Beijing Tiantan Hospital. It was published in Chinese Medical Journal (2021) with the DOI: doi.org/10.1097/CM9.0000000000001302.

Was this helpful?

0 / 0